Company Filing History:
Years Active: 2001
Title: Christoph Lurquin: Innovator in Cancer Research
Introduction
Christoph Lurquin is a notable inventor based in Brussels, Belgium. He has made significant contributions to the field of cancer research through his innovative work on nonapeptides. His research focuses on the interaction between these peptides and HLA molecules, which has important implications for diagnostics and therapeutics.
Latest Patents
Lurquin holds a patent for "Isolated nonapeptides presented by HLA molecules, and uses thereof." This invention involves nonapeptides bound by HLA molecules, such as HLA-A1. The resulting complexes are recognized by cytolytic T cells, which can be utilized in both diagnostic and therapeutic applications.
Career Highlights
Christoph Lurquin is affiliated with the Ludwig Institute for Cancer Research Limited. His work at this prestigious institution has allowed him to explore the potential of nonapeptides in cancer treatment and diagnosis. His innovative approach has garnered attention in the scientific community.
Collaborations
Lurquin has collaborated with esteemed colleagues, including Thierry R Boon-Falleur and Pierre Van Der Bruggen. These partnerships have enhanced his research and contributed to advancements in the understanding of cancer immunology.
Conclusion
Christoph Lurquin's contributions to cancer research through his patent on nonapeptides highlight the importance of innovation in the medical field. His work continues to pave the way for new diagnostic and therapeutic strategies in cancer treatment.